Full-Time

Staff Automation & Verification Lead

Posted on 9/7/2026

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

No salary listed

Bengaluru, Karnataka, India

Hybrid

Relocation assistance is provided.

Bachelor's, Master's

Category
QA & Testing (1)
Required Skills
Microsoft Azure
Python
Distributed Systems
GitHub Actions
Software Testing
Microsoft Windows
Docker
TypeScript
Risk Management
Jenkins
Playwright
REST APIs
Linux/Unix

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Computer Science, Software Engineering, Electrical Engineering, Biomedical Engineering, or another STEM discipline.
  • Advanced experience in software verification, quality engineering, or validation of regulated products, preferably in the medical device domain.
  • Extensive experience in software verification and test automation for complex software and medical device systems.
  • Strong programming skills in Playwright and TypeScript, Python, or similar languages, with emphasis on test automation and white-box and black-box testing techniques.
  • Experience developing and executing automated functional, integration, system, API, and regression tests.
  • Experience testing web services, REST APIs, cloud-native applications, and distributed systems.
  • Hands-on experience with continuous integration and continuous delivery tools such as Jenkins, Azure DevOps, or GitHub Actions.
  • Experience with test management, defect tracking, and requirements management tools.
  • Strong understanding of Linux/Unix and Windows environments.
  • Experience with virtualization, containers, simulated environments, hardware-in-the-loop, and device integration testing.
  • Strong knowledge of data-driven testing, pairwise testing, mocking, stubbing, fault injection, and test hooks.
  • Experience working within regulated environments following IEC 62304, ISO 13485, FDA requirements, EU MDR, and related standards.
  • Understanding of software verification and validation processes throughout the medical device lifecycle.
  • Experience with requirements traceability, risk-control verification, cybersecurity testing, and software safety classifications.
  • Familiarity with Design Controls, DHF, DMR, CAPA, Change Control, and Risk Management processes.
  • Strong analytical and problem-solving capabilities for evaluating complex technical and quality challenges.
  • Experience verifying scalable, reliable, and highly available healthcare systems and medical device software solutions.
  • Ability to decompose complex verification activities into well-defined tasks and provide realistic effort estimates.
Responsibilities
  • Own and lead verification activities for software and integrated medical device systems, ensuring compliance with product requirements, quality standards, and regulatory expectations.
  • Plan, develop, execute, and review verification protocols, test cases, and test reports for software, system, and hardware-software integrated solutions.
  • Ensure complete traceability between requirements, risks, design outputs, verification activities, and defects throughout the product lifecycle.
  • Drive risk-based verification strategies aligned with ISO 14971 and product risk management processes.
  • Collaborate with Systems, Software, Quality, Regulatory, Clinical, and Product teams to ensure comprehensive verification coverage.
  • Design, develop, and maintain scalable test automation frameworks for functional, integration, regression, performance, and system-level testing.
  • Develop automated test solutions for medical device software, cloud applications, connectivity solutions, and distributed systems.
  • Enhance test infrastructure, simulation environments, and continuous integration and continuous testing pipelines to improve product quality and release efficiency.
  • Create tools and utilities to improve test effectiveness, coverage analysis, defect detection, and traceability.
  • Ensure verification activities comply with IEC 62304, ISO 13485, FDA Quality System Regulation, EU MDR, and applicable cybersecurity requirements.
  • Support software release readiness activities by providing objective evidence of product quality and regulatory compliance.
  • Participate in design reviews, risk assessments, hazard analyses, and defect investigations.
  • Contribute to CAPA, audit responses, root cause investigations, and continuous quality improvement initiatives.
  • Define and promote verification best practices, testing methodologies, coding standards, and automation strategies across teams.
  • Mentor and coach junior verification engineers on test design, automation, regulatory compliance, and quality engineering practices.
  • Work closely with development teams to improve software testability, reliability, maintainability, and observability.
  • Lead defect triage activities, identify root causes, and ensure timely resolution of product quality issues.
  • Author, review, and maintain verification documentation, including test plans, protocols, reports, traceability matrices, and compliance records.
  • Provide clear status reporting and quality metrics to project stakeholders.
  • Support internal, customer, and regulatory audits by presenting verification evidence and quality documentation.
  • Champion quality, patient safety, continuous improvement, and engineering excellence across the organization.
Desired Qualifications
  • Experience supporting regulatory submissions and audit readiness activities.
  • Experience verifying scalable, reliable, and highly available healthcare systems and medical device software solutions.
  • Customer-focused understanding of how product quality, safety, reliability, and regulatory compliance affect patient outcomes and clinical workflows.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
  • Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
  • Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.

What critics are saying

  • Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
  • Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
  • If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.

What makes GE Healthcare unique

  • Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
  • GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
  • The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Associated Press
Aug 28th, 2026
GE HealthCare launches three new Vivid cardiovascular ultrasound systems for diverse care settings

GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.